ISLET SCIENCES INC

Inactive Instrument

News Islet Sciences Inc OTC Bulletin Board

Equities

US46467R1095

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Islet Sciences, Inc. Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH	15-05-04	GL
Islet Sciences, Inc. Presented at 50th International Liver Conference	15-04-23	GL
Islet Sciences, Inc. COO to Present at Metabolic Leaders Forum	15-03-24	GL
Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)	15-03-09	GL
Islet Sciences, Inc. Confirms Issuance of U.S. Patent for Using SGLT2 Inhibitors to Treat NASH/NAFLD	15-03-05	GL
Islet Sciences Enters Into Exclusive License Agreement for Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate	15-03-03	GL
Islet Sciences Engages Investment Bank as Financial Advisor	15-02-09	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Stock Market
Equities
ISLT Stock
Stock
News Islet Sciences Inc

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer